An innovative medical technology for bladder cancer treatment.
Theralase® Technologies Inc. is a biopharmaceutical company headquartered in Toronto, Canada focused on the design, development, manufacturing, and sale of patented laser technology platforms used in a wide range of bio-stimulative and bio-destructive clinical applications in patients.
Founded in 1994, Theralase’s operations are divided into two divisions: the production of therapeutic laser technology for commercial applications, and the research and development of laser-based technologies for the destruction of cancer cells and other disease states.
Theralase® focuses on the development of laser-based non-invasive therapeutic devices to eliminate pain, reduce inflammation, and accelerate tissue healing.
Their patented TLD-1433 photo dynamic compound has now successfully completed a Phase 1b Clinical Study for Non-Muscle Invasive Bladder Cancer (“NMIBC”).
For more information on Theralase Technologies Inc. (TLT:TSX.V, TLTFF:OTCQX) please fill out the form below.